Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 1,500 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 1,500 shares of the business's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $12.00, for a total transaction of $18,000.00. Following the transaction, the general counsel directly owned 469,301 shares of the company's stock, valued at approximately $5,631,612. This trade represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alphatec Stock Down 0.7%

Shares of Alphatec stock traded down $0.08 on Monday, hitting $10.91. 720,393 shares of the company traded hands, compared to its average volume of 1,949,904. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $13.14. The company has a market cap of $1.59 billion, a PE ratio of -9.49 and a beta of 1.05. The company has a 50-day moving average price of $11.87 and a 200 day moving average price of $11.04.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The business had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company's revenue for the quarter was up 22.2% on a year-over-year basis. Equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

ATEC has been the topic of several recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target on the stock in a report on Monday, June 16th. Piper Sandler reissued an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its stake in shares of Alphatec by 301.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock worth $608,000 after acquiring an additional 45,027 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after purchasing an additional 2,306 shares during the period. SG Americas Securities LLC boosted its holdings in Alphatec by 28.3% in the 1st quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock valued at $577,000 after purchasing an additional 12,553 shares during the period. Oppenheimer Asset Management Inc. grew its position in Alphatec by 13.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock worth $133,000 after purchasing an additional 1,552 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Alphatec by 6.9% during the 1st quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock worth $1,508,000 after purchasing an additional 9,661 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.